| Literature DB >> 35146151 |
Chinonso Anthony Ezema1,2, Timothy Prince Chidike Ezeorba3, Rita Ngozi Aguchem3, Innocent Uzochukwu Okagu3.
Abstract
Man is increasingly being faced with many health conditions, including viral infection, some of which increases the risk to cancer. These infectious agents contribute to the large number of persons with cancer and the worrisome number that die from the diseases. A good range of drugs are currently in place for treating patients infected with viruses, however, some of the drugs' effectiveness are limited by the emergence of drug-resistant strains of the viruses, as well as adverse effects of the drugs. Similarly, the inability of many anticancer drugs to selectively kill cancer cells while sparing hosts' normal cells limit their use. This warrants more research for newer drugs, especially from chemicals naturally encrypted in plants with anticancer and antiviral activities. In response to infection with cancer-inducing viruses, plants such as Salvia species synthesize and store secondary metabolites to protect themselves and kill these viruses as well as inhibit their ability to induce carcinogenesis. Hence, this review presented a discussion on the potential application of Salvia species in the prevention and management of cancer and viral infection. The study also discusses the cellular mechanisms of action of these herbal products against cancer cells and viruses, where available and provided suggestions on future research directions. The study is believed to spur more research on how to exploit Salvia phytochemicals as candidates for the development of nutraceuticals and drugs for managing cancers and viral infection.Entities:
Keywords: Anticancer; Antiviral; Nutraceuticals; Phytochemicals; Salvia species
Year: 2022 PMID: 35146151 PMCID: PMC8819530 DOI: 10.1016/j.heliyon.2022.e08763
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Summary of anticancer effects of Salvia spp extracts and phytochemicals.
| Concentration tested/dose administered | Study model (cell lines or animal models) | Pharmacological effects | References | |
|---|---|---|---|---|
| Water extract of | 13.3 g/l | Female Fischer 344 rats | Reduced AOM-induced DNA damages on colonocytes and on lymphocytes by 20% and 65% respectively. Reduced H2O2-induced DNA damages on colonocytes by 28%. Reduced AOM-induced proliferation by 30.5%. Reduced AOM-induced ACF formation by 53%. | [ |
| Hydro-ethanol extract of | 6.25–1000 μg/ml | AGS and MKN-45 | Suppressed proliferation of AGS (IC50 = 9.262 μg/ml) and MKN-45 (IC50 = 271.73 μg/ml) cells. | [ |
| PDE sub-fractions of methanol extracts of | 25–200 μg/ml | MCF-7 and PC-3 | Reduced viability of MCF-7 and PC-3 cell lines, with IC50 values ranging from 24.19 to 47.15 μg/ml. PDE sub-fractions induced apoptosis in PC-3 cells with DCM sub-fraction increasing the Bax/Bcl-2 ratio by 650% compared to negative control, and cleaving PARP | [ |
| Petroleum ether sub-fractions of methanol extracts | 2.5–200 μg/ml | PC-3, MCF-7 and MDA-MB-231 | Reduced proliferation of PC-3 (IC50 = 8.73 μg/ml), MCF-7 (IC50 = 32.40 μg/ml) and MDA-MB-231 (IC50 = 77.65 μg/ml) by cleaving PARP. | [ |
| N.D | A549, MCF-7, MDA-MB-231 and normal HDF | Cytotoxic against A549, MCF-7, MDA-MB-231 and HDF with IC50 values of 20.89, 10.24, 20.98 and 26.90 μg/ml, respectively. | [ | |
| Dichloromethane:methanol extract of | 5–150 μg/ml | PC-3 | Cytotoxic against the cancer cell and inhibited its migrationPC-3 cells (IC50 = 19.72 μg/ml) by increasing level of PARP cleavage by 75% (compared to control). The extract suppressed the migration of PC-3 cells by 48% via reduction in total AKT phosphorylated AKT by 27% and 70%), while total mTOR and phosphorylated mTOR reduced by 40% and 65%, respectively. | [ |
| DMSO extract of | 2–10 μg/ml | 184-B5/HER | Inhibited the proliferation of 184-B5/HER cells (IC50 = 4.6 μg/ml) by inducing cell cycle arrests at G1 and G2/M phases and inducing apoptosis (increased Bax/Bcl-2 ratio by 225%). | [ |
| Methanol extract of | 200 mg/kg b.w for | HGUE-C-1, SW480, and HT-29 cells as well as athymic mice | Induced necrosis in HGUE-C-1, HT-29 and SW480 cells. At 40 μg/ml, RE increased LDH leakage in HGUE-C-1, SW480 and HT-29 cells by 32.6%, 20.0% and 14.3%, respectively, increased ROS generation by 280, 300 and 250%, respectively; and decreased MMP by 35, 40 and 30%, respectively. At 30 and 40 μg/ml, RE inhibited the migration of HGUE-C-1 cells by 28.8 and 66.1%, respectively, HT-29 cells by 22.1 and 92.5%, respectively and SW480 cells by 5.6 and 76.7%, respectively. | [ |
| A mixture of saprorthoquinone and aethiopinone | 2.5–100 μg/ml | PC-3, MCF-7 and MDA-MB-231 | Cytotoxic against PC-3 (IC50 = 8.83 μg/ml), MCF-7 (IC50 = 26.15 μg/ml) and MDA-MB-231 (IC50 = 66.23 μg/ml) by increasing PARP cleavage (increased PARP cleavage by 220% at 12.5 μg/ml); increasing caspase-3 level (increased caspase-3 level by 1700% at 6.25 μg/ml); and increasing Bax/Bcl-2 ratio (increased Bax/Bcl-2 ratio by 200% at 6.25 μg/ml). | [ |
| 13-Epimanoyl oxide | N.D | A549, MCF-7, MDA-MB-231 and normal HDF | Cytotoxic against A549, MCF-7 and MDA-MB-231 with IC50 values of 19.37, 15.79 and 22.24 μg/ml, respectively. | [ |
| Aegyptinone A and tebesinone B | N.D | MCF-7, B16F10, PC-3, and C26 | Aegyptinone A inhibited viability of MCF-7, B16F10, PC-3 and C26 cells (with IC50 values of 4.82, 4.82, 1.24 and 4.09 μg/ml, respectively while the IC50 values of tebesinone B against the cancer cells were 4.45, 6.09, 3.22 and 3.23 μg/ml, respectively by. | [ |
| Taxodione and sahandinone | N.D | MOLT-4, HT-29) and MCF-7 | Cytotoxic against MOLT-4, HT-29 and MCF-7 (with IC50 values of 0.54, 2.76 and 3.87 μg/ml, respectively by taxodione and IC50 values of 0.41, 1.78 and 3.20 μg/ml, respectively by sahandinone. | [ |
| Taxodione | 0 - 30 mΜ | BCR-ABL-positive K562 cells | Inhibited proliferation (IC100 = 17.66 μg/ml) and induced apoptosis by 120% upregulation of ROS generation. | [ |
| 15-deoxyfuerstione, horminon, microstegiol and 14-deoxycoleon U | N.D | K562 and MCF-7 | The phytochemicals were toxic to both cells via inhibition of topoisomerase I. The IC50 values of 15-deoxyfuerstione, horminon, microstegiol and 14-deoxycoleon U were 4.70, 9.60, 3.30 and 2.63 μg/ml, respectively against K562 and 5.13, 11.8, 4.67 and 2.70 μg/ml, respectively against MCF-7. | [ |
| Ferruginol (FRG) | 6–48 μM | MCF-7 | Induced apoptosis via 340% increase in caspase-3, 225% increase in caspase-9, 400% increase in TBARS, and 271.4% increase in ROS generation. It also reduced the levels of NF-κB, MMP, SOD, CAT and GSH by 65%, 62.5%, 72, 68.4 and 72% respectively. | [ |
| 10–320 μM | SK-Mel-28 | Cytotoxic against SK-Mel-28 (IC50 = 50.03 μg/ml) by elevating caspase-3-mediated apoptosis. | [ | |
| Chrysin | 5–100 μM | ES2 and OV90 | Induced apoptosis through the loss of MMP (by 350% and 50%, respectively), and increase in cytoplasmic Ca2+ level (by 550% and 275%, respectively) and ROS generation (by 450% and 120%, respectively). | [ |
| 10–160 μM and 20 mg/kg b.w.for in vivo study | MKN-45 cells nude mice | Cytotoxic to MKN-45 cells at ≥ 80 μM by increasing Bax/Bcl-2 ratio and TET1 enzymes (by 167%). At 40 μM chrysin reduced MKN-45 cells' migration and invasion by about 44 and 72%, respectively via elevation in TET1 expression by 61.54%. Oral administration of chrysin at 20 mg/kg.bw inhibited tumor growth by reducing 20% of tumor volume and upregulating the expression of TET1 enzymes by 50%. | [ | |
| 10–200 μg/ml and 8 and 10 mg/kg b.w. | CT-26 and mice | Induced apoptosis in CT26 cells (IC50 = 80 μg/ml) through elevation in caspase-3 and caspase-9 activities by 97.9 and 126.7% respectively. 2-week oral administration of chrysin at 8 and 10 mg/kg.bw to mice resulted in about 21 and 37% reduction in CT-26 tumor volume respectively by decreasing sall4 level and increasing Bax level. | [ | |
| 125 and 250 mg/kg.bw for | SW620 cells for cell culture study and male albino rat for | Inhibited proliferation of SW620 cells (IC50 value = 70 μM) via reduction in p-ERK/ERK and p-AKT/AKT ratios by 51 and 24.8% respectively. Treatment of rats with 125 and 250 mg/kg.bw of chrysin for 8–16 weeks inhibited DMH-induced tumorigenesis by reducing CYP2E1 level (by 7.7 and 45%, respectively) MDA level (by 32.7 and 35.3%, respectively), NO level (by 22.8 and 31.4%, respectively), CXCL1 level (by 27.7 and 55.6%, respectively), AREG level (by 21 and 27.4%, respectively), and MMP-9 level (by 21.33 and 47%, respectively), as well as increasing GSH level (by 67.3 and 188.5 %, respectively). | [ | |
| DHTS | 1.25–5 μM and 10 mg/kg b.w. | EOMA cells and mice | At 1.25 and 2.5 μM, DHTS inhibited the ability of EOMA cells to align and form tubes through reduction in expression of VEGFR2 and MMP-9 by 28.2% and 77%, respectively. At 10 mg/kg bw, DHTS also depressed the expression of VEGFR2 and MMP-9 in mice. | [ |
| Rosmarinic acid | 4–16 mg/kg b.w | Male Wistar rat models | For 4, 8 or 16 mg/kg bw. treatments, there were respective reductions in DNA damages by 55.2, 55.4 and 49%, and reductions in ACF formation in the distal colon by 62.7, 65.4 and 59.5%. | [ |
| Manool | 0.5–2.0 μg/ml (for in vitro genotoxicity test), 0.5–4 μg/ml for ex vivo NO synthesis test, 1.25–20.0 mg/kg bw for in vivo genotoxicity assay, and 0.3125–5.0 mg/kg bw for ACF assay | V79 cells (for in vitro genotoxicity test), macrophages (for LPS-induced NO synthesis), rats (for ACF assay) and mice (for in vivo genotoxicity assay) | At 0.5 μg/ml, manool depressed DXR-generated micronuclei formation in V79 cells by 64.54%; at 0.5 and 1.0 μg/ml, manool inhibited hydrogen peroxide-induced micronuclei formation in V79 cells by 37 and 40% respectively and also suppressed LPS-induced NO synthesis in macrophages by 15.0% and 21.6% respectively. At 0.3125–5.0 mg/kg b.w. dose rage, manool reduced ACF formation in rats by 59.7–84.7% and reduced DXR-induced chromosomal damage in mice by 79.5% at 1.25 mg/kg b.w. | [ |
Abbreviations: N.D = not defined; DHTS = 15,16-Dihydrotanshinone I; DCM = dichloromethane; PDE = petroleum ether, dichloromethane and ethyl acetate subfraction; NO = nitric oxide; LPS = lipopolysaccharides; MMP = mitochondrial membrane potential; TBARS = thiobarbituric acid reactive substance; SOD = superoxide dismutase; GSH = reduced glutathione; ROS = reactive oxygen species; AOM = azoxymethane; ERK = extracellular signal-regulated protein kinase; AKT = protein kinase B; VEGFR2 = vascular endothelial cell growth factor receptor 2; LDH = lactate dehydrogenase; CAT = catalase; ACF = aberrant crypt foci; DNA = deoxyribonucleic acid; DXR = doxorubicin; NF-kB = nuclear factor kappa B; mTOR = mammalian target of rapamycin.
Figure 1Proposed mechanisms of anti-cancer activities of phytochemicals from Salvia spp. 1) Induction of plasma membrane permeabilization in cancer cells; 2) Reduction of anti-oxidant status of cancer cells and suppression of angiogenesis and metastasis markers; 3) Elevation of ROS in cancer cells; 4) Induction of MOMP; 5) Suppression of ATP production. Phytochemicals from Salvia spp induce plasma membrane permeabilization in cancer cells, leading to death by necrosis. They also elevate ROS production, leading to activation of p53, which induce cell cycle arrest and senescence via p21. P53 also induce the intrinsic apoptotic pathway via upregulation in expression of BH3-only molecules (e.g. PUMA and Noxa). BH3-only molecules elevate the levels of pro-apoptotic molecules (Bax and Bak) and depress the levels of anti-apoptotic molecules (Bcl-2). Induction of MOMP by Bax and/or Bak lead to release of cytochrome C, leading to apoptosis. Induction of MOMPS also leads to ATP depletion (suppression of ATP production), which can lead to death by necrosis. Salvia spp phytochemicals also suppress the levels of anti-oxidant molecules in cancer cells, allowing membrane lipids' peroxidation (which can also activate p53 to bring about cell death). Salvia spp phytochemicals also suppress angiogenesis and metastasis markers. Abbreviations: ROS = Reactive oxygen species; MOMP = Mitochondrial outer membrane permeabilization; ATP = Adenosine triphosphate; CDK 1 = Cyclin-dependent kinase-1; APAF-1 = Apoptosis protein activating factor-1; Bax = Bcl-2-associated X protein; Bak = Bcl-2 homologous antagonist/killer; BH-3 = Bcl-2 homology 3; PUMA = p53 upregulated modulator of apoptosis.
Antiviral activities of extracts of Salvia species and their phytochemicals.
| Virus | Cell culture, Study model | Assay | Duration of treatment/Incubation time | Activities (IC50/EC50) | References | |
|---|---|---|---|---|---|---|
| HSV-1 | MDBK and Vero cell lines | cytopathogenic effect (CPE) concentrations | 48 h | 16–1.0 mg/ml against both HSV-1 and PI-3 | [ | |
| H1N1 | MDCK cells | plaque reduction assay (PRA) | 108 h | 93% | [ | |
| HSV-1 | MDBK and Vero cell lines | cytopathogenic effect (CPE) concentrations | 48 h | 16–1.0 mg/ml against both HSV-1 and PI-3 | [ | |
| H7N7, H3N2,HSV-1 & HSV-2 | MDCK and MDBK cells | Cytopathogenic effect (CPE) reduction assay | 24 h | 0.30 mg/ml (H7N7), 0.60 mg/ml (H3N2), 0.60 mg/ml (HSV-1) & 0.50 mg/ml (HSV-2) | [ | |
| Acyclovir sensitive (AS) and Acyclovir resistant (AR) strains | Vero, (ATCC CCL-81), the epithelial cell lines Hep-2 (ATCC CCL-23) and A549 (ATCC CCL-185) | HSV inhibition assay | 2 h | 23.72 μg/ml (AS) 28.57 μg/ml (AR) | [ | |
| HSV-1 | Vero cells | plaque assay | 48 h | 0.2% oil fraction inhibits 80 % PFU | [ | |
| HSV-1 and HSV-2 | MDCK and MDBK | Cytopathic effect (CPE) reduction assay. | 48–72 h | 0.12 (mg/ml) (HSV-1) & 0.05 (mg/ml) (HSV-2) | [ | |
| EV71 | Vero, MRC-5 & rhabdomyosarcoma cells | Plaque Assay, Cytopathic Effect Test & MTT Assay | 3 h | 0.742 mg/ml (SA1) | [ | |
| EV71 | COS-1 cell line | Cytotoxicity & Anti-EV71 infection assays | 48 h | MLB IC50 value -0.09 mM | [ | |
| HSV-1 | WISH human amnion epithelial cells | reduction of CPE | 5 h | 199.0 μg/ml | [ | |
| HSV-1 | Vero cells | inhibition of plaque formation | 48 h | 1.41–1.88 μg/ml | [ | |
| HSV-1 and HSV-2 | RC-37 cells | Reduction in plague formation assays | 72 h | 0.18 μg/ml (HSV-1) & 0.04 μg/ml (HSV-2) | [ | |
| H5N1 | MDCK cells | Plaque reduction assay | 72 h | (IC50) 0.41 μg/ml | [ | |
| H1N1 | MDCK cells | Cytopathic Effect (CPE) Inhibition Assay | 24 h | 6.58–11.67 μg/ml | [ | |
| RSV | RPMI 1640 culture solution | MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetr-azolium bromide] assay | 48 h | 60 % lung index inhibition ratio with high dose High-dose (17.6 mg/20 g/d) of treatment | [ | |
| H1N1 | MDCK cells | Cytopathic effect (CPE) reduction method. | 48 h | CPE inhibition of 52% greater than the standard drug oseltamivir, with no cytotoxicity at a concentration of 100 μg/ml | [ | |
| (H7N7) | MDCK and MDBK cells | Cytopathic effect (CPE) reduction assay. | 48–72 h | 0.13 (mg/ml) (H7N7) | [ |
Abbreviations: Herpes simplex (type-1) (HSV-1); parainfluenza (type-3); chicken influenza virus (H7N); human influenza virus (H3N2); Enterovirus 71 (EV71); avian influenza virus H5N1; respiratory syncytial virus (RSV); Madin-Darby bovine kidney (MDBK) cell lines; Madin-Darby canine kidney (MDCK); African green monkey fibroblastoid kidney cells (Vero cell).
Figure 2Structures of some compounds from Salvia spp with anticancer and antiviral properties. Key: Green colour represents carbon chain, red colour represents oxygen atom, blue colour represents nitrogen atom while white colour represents hydrogen atom. Vitamin C (1), Rosmarinic acid (2), Rosmarinic acid methyl ester (3), Manool (4), Chrysin (5), Saprorthoquinone (6), Aethiopinone (7), Epimanoyl oxide (8), Ferruginol (9), Taxodione (10), Sahandinone (11), 4-Dehydrosalvilimbinol (12), 15-Deoxyfuerstione (13), Horminon (14), Microstegiol (15), 14-Deoxycoleon (16), 15,16-Dihydrotanshinone I (17), 13-Epimanoyl oxide (18), Rutin (19), Luteolin (20), 6-Hydroxyluteolin 7-O-β-d-glucoside (21), Nepitrin (22), Homoplantaginin (23), Hispidulin (24), Nepetin (25), Lactic acid (26), Caffeic acid (27), Salvianolic acid (28) & Cappariloside A (29).